当前位置: X-MOL 学术Antivir. Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Adoptive T-cell therapy for HBV-associated HCC and HBV infection.
Antiviral Research ( IF 7.6 ) Pub Date : 2020-02-19 , DOI: 10.1016/j.antiviral.2020.104748
Anthony T Tan 1 , Sophia Schreiber 2
Affiliation  

Chronic hepatitis B virus (HBV) infection remains a major global concern due to its high prevalence and the increased probability of progressing toward cirrhosis and hepatocellular carcinoma (HCC). While currently available therapies are effective in controlling HBV replication, they rarely achieve functional cure. Similarly, effective treatment options for HBV-related HCC (HBV-HCC) are limited and primarily applicable only for early stages of the disease. With the general success of chimeric antigen receptor T-cell immunotherapy against B-cell leukemia, adoptively transferring engineered autologous T cells specific for HBV or HCC antigens might represent a promising therapeutic approach for both chronic HBV infection and HBV-HCC. This review will describe the novel T cell-related immunotherapies being developed for both indications and discuss the approach of each strategy, their considerations and limitations when applied for treatment of chronic HBV infection (CHB) and HBV-HCC.

中文翻译:

用于HBV相关HCC和HBV感染的过继性T细胞疗法。

慢性乙型肝炎病毒(HBV)感染由于其高患病率以及发展为肝硬化和肝细胞癌(HCC)的可能性增加,仍然是全球关注的主要问题。尽管目前可用的疗法可有效控制HBV复制,但很少能达到功能治愈。同样,针对HBV相关HCC(HBV-HCC)的有效治疗选择也很有限,并且主要仅适用于疾病的早期阶段。随着针对B细胞白血病的嵌合抗原受体T细胞免疫疗法的普遍成功,对HBV或HCC抗原特异的过继工程改造的自体T细胞的过继转移可能代表慢性HBV感染和HBV-HCC的有前途的治疗方法。
更新日期:2020-02-20
down
wechat
bug